Extended Data Fig. 5: Neutralising responses in patients with cancer and healthy controls.
a) NAbT against WT SARS-CoV-2, Alpha, Beta, and Delta in infection naive, healthy individuals (n = 55, by age: 39/16), patients with solid cancers (n = 48, by age: 9/39) and haematological malignancies (n = 24, by age: 5/19) after two doses of Pfizer. Median fold-decrease in NAbT is shown for each VOC in comparison to WT SARS-CoV-2. Dotted line at <40 denotes the lower limit of detection, dotted line at >2560 denoted the upper limit of detection. Violin plots denote density of data points. PointRange denotes the median and the 25 and 75 percentiles. Dots represent individual samples. Significance was tested by Kruskal Wallis test, p < 0.05 was considered significant, post-hoc test: two-sided Wilcoxon Mann-Whitney U test with Bonferroni correction was used for pairwise comparisons. ns, non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001. b) NAbT were categorised as undetectable/low (<40), medium (40-256), or high (>256) are shown for WT SARS-CoV-2 and the three VOCs. Differences were analysed using Chi-Square test. p-values < 0.05 were considered significant. Patient numbers per category are annotated in graph. c) NAbT against WT SARS-CoV-2, Alpha, Beta, and Delta in, healthy individuals (n = 8), patients with solid cancers (n = 77) and haematological malignancies (n = 18) after two doses of AZ. Median fold-decrease in NAbT is shown for each VOC in comparison to WT SARS-CoV-2. Dotted line at <40 denotes the lower limit of detection, dotted line at >2560 denoted the upper limit of detection. Violin plots denote density of data points. PointRange denotes the median and the 25 and 75 percentiles. Dots represent individual samples. Significance was tested by Kruskal Wallis test, p < 0.05 was considered significant, post-hoc test: two-sided Wilcoxon Mann-Whitney U test with Bonferroni correction was used for pairwise comparisons. ns, non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001. d) NAbT were categorised as undetectable/low (<40), medium (40-256), or high (>256) are shown for WT SARS-CoV-2 and the three VOCs. Differences were analysed using Chi-Square test. p-values < 0.05 were considered significant. Patient numbers per category are annotated in graph. NAbT, neutralizing antibody titre.
